Cannabis Strategic Ventures (OTCPK: NUGS)
Health Care · Pharmaceuticals · US
$0.00
+150.00% today · +99900.0% 1Y
Cannabis Strategic Ventures (OTCPK: NUGS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $402.30K and employs 30 people.
Over the last twelve months the share price has gained 99900.0%, trading between 0.00 and 0.01.
Tweenvest scores Cannabis Strategic Ventures across four factors: quality 8/100, value 44/100. Its strongest factor is value.
NUGS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $402.30K
- Revenue (TTM)
- $14.60M
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- -89.32
- 52-week high
- $0.01
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 402.29M
- Employees
- 30
- Next earnings
- —
About Cannabis Strategic Ventures
Cannabis Strategic Ventures specializes in cultivating cannabis products across the United States. Beyond its growing operations, the firm actively fosters new ventures, expands existing operations, and forms strategic alliances within the broader cannabis ecosystem and its supporting sectors. Its corporate headquarters are situated in Los Angeles, California.
- ISIN
- US13765M1099
- Listed since
- Jul 24, 2009
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,247.37 | -0.64% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $273.00 | +1.02% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.91 | -1.08% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.03 | -0.14% |
Figures last refreshed Aug 18, 2026.